The (ITI) share price is expected to decrease by NAN% over the next year. This is based on calculating the average 12-month share price estimate provided by 0 stock analysts who have covered ITI. Price targets range from $ at the low end to $ at the high end. The current analyst consensus for ITI is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assignedITI 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect to sell. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on ITI. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of ITI.
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
---|---|---|---|---|
Data Not Found! |
In 2023, ITI generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that ITI's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Summary - Iteris, Inc. has been acquired by Almaviva S.p.A., resulting in its common stock ceasing to trade on NASDAQ and being delisted from public markets. Iteris will operate as a separate entity.
Why It Matters - Iteris' acquisition by Almaviva results in its delisting from NASDAQ, impacting liquidity and market access for investors. The transition may affect future growth and valuation expectations.
Summary - Iteris, Inc. stockholders approved the merger with Almaviva S.p.A. in an all-cash transaction, as announced at a Special Meeting held recently.
Why It Matters - The approval of Iteris' merger with Almaviva indicates a consolidation in the smart mobility sector, potentially impacting stock performance, market dynamics, and investor sentiment.
Summary - Kahn Swick & Foti, LLC is investigating the proposed sale of Iteris, Inc. to Almaviva S.p.A., where shareholders would receive $7.20 per share. They are assessing the adequacy of this offer.
Why It Matters - The investigation into Iteris' sale could impact shareholder value and perceptions of the deal's fairness, influencing market sentiment and trading decisions.
Summary - Halper Sadeh LLC is investigating the fairness of Iteris, Inc.'s sale to Almaviva S.p.A. for $7.20 per share, urging shareholders to explore their legal rights.
Why It Matters - The investigation into Iteris' sale price could signal potential legal challenges or a reconsideration of the deal, impacting share value and investor confidence.
Summary - Monteverde & Associates is investigating Iteris, Inc. regarding its merger with Almaviva S.p.A., which will convert Iteris shares to $7.20 in cash.
Why It Matters - The investigation into Iteris' merger could impact shareholder value and confidence, especially regarding the cash conversion rate, influencing investment decisions.
Summary - Monteverde & Associates PC, recognized as a Top 50 firm in the ISS Securities Class Action Services Report (2018-2022), has successfully recovered funds for shareholders.
Why It Matters - Recognition of Monteverde & Associates as a top firm in securities class actions highlights their effectiveness in recovering shareholder funds, potentially boosting investor confidence in their services.